237 related articles for article (PubMed ID: 27334764)
1.
Lee SE; Choi SY; Kim SH; Song HY; Yoo HL; Lee MY; Kang KH; Hwang HJ; Jang EJ; Kim DW
Korean J Intern Med; 2017 Jan; 32(1):125-136. PubMed ID: 27334764
[TBL] [Abstract][Full Text] [Related]
2. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
Asnafi V; Rubio MT; Delabesse E; Villar E; Davi F; Damaj G; Hirsch I; Dhédin N; Vernant JP; Varet B; Buzyn A; Macintyre E
Leukemia; 2006 May; 20(5):793-9. PubMed ID: 16541140
[TBL] [Abstract][Full Text] [Related]
3. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
4. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.
Olavarria E; Kanfer E; Szydlo R; Kaeda J; Rezvani K; Cwynarski K; Pocock C; Dazzi F; Craddock C; Apperley JF; Cross NC; Goldman JM
Blood; 2001 Mar; 97(6):1560-5. PubMed ID: 11238091
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
Arpinati M; Tolomelli G; Bochicchio MT; Castagnetti F; Amabile M; Bandini G; Bonifazi F; Stanzani M; Rosti G; Martinelli G; Baccarani M
Biol Blood Marrow Transplant; 2013 May; 19(5):735-40. PubMed ID: 23333776
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
7. Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion.
Otazú IB; Tavares Rde C; Hassan R; Zalcberg I; Tabak DG; Seuánez HN
Leuk Res; 2002 Feb; 26(2):129-41. PubMed ID: 11755463
[TBL] [Abstract][Full Text] [Related]
8. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
9. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
[TBL] [Abstract][Full Text] [Related]
11. [Follow-up detection of M-bcr/abl and m-bcr/abl fusion transcripts in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation].
Qin YZ; Liu YR; Li JL; Fu JY; Chang Y; Ruan GR; Wang H; Qiu JY; Lu DP; Chen SS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Aug; 11(4):368-71. PubMed ID: 12962564
[TBL] [Abstract][Full Text] [Related]
12. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
[TBL] [Abstract][Full Text] [Related]
13. [The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse].
Xu LP; Liu KY; Huang XJ; Liu DH; Han W; Chen YH; Wang Y; Liu YR; Qin YZ
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):522-5. PubMed ID: 19112914
[TBL] [Abstract][Full Text] [Related]
14. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
[TBL] [Abstract][Full Text] [Related]
16. [Real-time reverse-transcriptase polymerase chain reaction in monitoring BCR/ABL transcript levels in chronic myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation].
Tang BL; Cheng M; Liu HL; Geng LQ; Wu ZT; Sun ZM
Zhonghua Nei Ke Za Zhi; 2007 Mar; 46(3):224-8. PubMed ID: 17547807
[TBL] [Abstract][Full Text] [Related]
17. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.
Ballestrero A; Cirmena G; Dominietto A; Garuti A; Rocco I; Cea M; Moran E; Nencioni A; Miglino M; Raiola AM; Bacigalupo A; Patrone F
Int J Lab Hematol; 2010 Aug; 32(4):387-91. PubMed ID: 19968720
[TBL] [Abstract][Full Text] [Related]
19. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
[TBL] [Abstract][Full Text] [Related]
20. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
